Monday, July 15, 2024

JOHNSON & JOHNSON Affirms Decision to Waive SIRTURO® (bedaquiline) Patents for Treating Multidrug-Resistant Tuberculosis in 134 Low- and Middle-Income Nations

Similar articles

Johnson & Johnson has announced its decision not to enforce its patents for SIRTURO® (bedaquiline) in the treatment of multidrug-resistant tuberculosis (MDR-TB) in 134 low- and middle-income countries. This move aims to encourage generic manufacturers to produce and sell high-quality generic versions of SIRTURO® in these countries without concerns about patent enforcement. However, the generics must meet quality and medical standards and be used exclusively in the designated countries.

The decision reflects Johnson & Johnson’s commitment to address the primary barrier to MDR-TB treatment, which is underdiagnosis, with a significant percentage of cases going untreated each year. The company has invested heavily in collaborative efforts over the past decade to enhance access to MDR-TB treatment.

SIRTURO® (bedaquiline) was introduced by Johnson & Johnson in 2012 as the first targeted tuberculosis medicine with a novel mechanism of action in over 40 years. Through partnerships and investments, the company has played a crucial role in improving TB treatment systems, healthcare professional training, resistance testing, surveillance, and supply chain security. Bedaquiline is now a key component of World Health Organization-recommended treatment guidelines for drug-resistant TB.

Furthermore, Johnson & Johnson recently granted a license to the Stop TB Partnership’s Global Drug Facility, enabling the procurement and supply of generic versions of SIRTURO® for most low- and middle-income countries. The company remains dedicated to building capacity, enhancing surveillance, and improving patient access to bedaquiline.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article